Dr Eric Berg, D.C., an established health educator and best-selling author, has publicly aligned with Robert F. Kennedy Jr. in a call for greater transparency and integrity in vaccine science and health policy. Widely recognised for his expertise in nutrition and holistic health, Dr Berg has raised concerns over weaknesses in vaccine safety testing--particularly the practice of using active vaccines as comparators instead of inert placebos--and the potential for conflicts of interest within major health authorities. By collaborating with Kennedy, a long-standing campaigner for corporate accountability, Dr Berg highlights a growing movement that is pushing for unbiased research, open discussion, and meaningful informed consent. Their joint aim is to give individuals the ability to make their own health decisions based on transparent, comprehensive data, while challenging the role of pharmaceutical interests in shaping public health institutions.
ALEXANDRIA, Va. – Dr Eric Berg, D.C., a respected health educator and best-selling author, today declared his strong alignment with Robert F. Kennedy Jr. in promoting transparency and scientific rigour within public health, especially in relation to vaccines and policy. Known for his work in nutrition and holistic medicine, Dr Berg stresses the importance of impartial research and open debate about vaccine safety, echoing Kennedy's criticism of pharmaceutical influence over health agencies.
Dr Berg's position follows his examination of vaccine science, where he identifies what he considers fundamental weaknesses in current safety trial methods. "The prevailing practice of comparing new vaccines against other active vaccines, rather than inert placebos, creates a misleading picture of safety," states Dr. Berg. "This approach can obscure potential adverse effects, particularly those linked to adjuvants like aluminum, which have been implicated in conditions such as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)."
His concerns also extend to possible conflicts of interest within leading health institutions. Dr Berg highlights examples such as the Centres for Disease Control and Prevention (CDC) holding vaccine patents and receiving royalties, which he believes may compromise impartiality in their public health guidance.
Robert F. Kennedy Jr., an environmental lawyer and long-time public health advocate, has consistently challenged both the pharmaceutical industry and government policies. Dr Berg commends Kennedy's determination: "RFK Jr. has a proven track record of successfully challenging powerful corporations and fighting for the truth," Dr. Berg asserts. "His legal expertise and dedication to uncovering corruption are precisely what is needed to bring much-needed reform and integrity to our public health institutions."
The partnership between Dr Berg and Kennedy signals the rise of a movement demanding more transparent and honest conversations around medical interventions. Both stress that genuine informed consent--grounded in full and transparent scientific data--is essential if individuals are to make independent health choices.
Dr Berg Nutritionals continues to focus on equipping people with knowledge and resources to achieve health through natural and holistic methods. This collaboration with Robert F. Kennedy Jr. strengthens their shared commitment to question prevailing narratives and promote a health model built on scientific integrity and public well-being.
source:newsreleases.co.uk
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137